169 related articles for article (PubMed ID: 6298516)
1. Different receptors mediate morphine-induced prolactin and growth hormone release.
Spiegel K; Kourides IA; Pasternak GW
Life Sci; 1982 Nov 15-22; 31(20-21):2177-80. PubMed ID: 6298516
[TBL] [Abstract][Full Text] [Related]
2. Prolactin and growth hormone release by morphine in the rat: different receptor mechanisms.
Spiegel K; Kourides IA; Pasternak GW
Science; 1982 Aug; 217(4561):745-7. PubMed ID: 6285470
[TBL] [Abstract][Full Text] [Related]
3. Differential role of the opioid mu and delta receptors in the activation of prolactin (PRL) and growth hormone (GH) secretion by morphine in the male rat.
Koenig JI; Mayfield MA; McCann SM; Krulich L
Life Sci; 1984 May; 34(19):1829-37. PubMed ID: 6330479
[TBL] [Abstract][Full Text] [Related]
4. Naloxonazine actions in vivo.
Ling GS; Simantov R; Clark JA; Pasternak GW
Eur J Pharmacol; 1986 Sep; 129(1-2):33-8. PubMed ID: 3021478
[TBL] [Abstract][Full Text] [Related]
5. Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro.
Pasternak GW; Childers SR; Snyder SH
J Pharmacol Exp Ther; 1980 Sep; 214(3):455-62. PubMed ID: 6105201
[TBL] [Abstract][Full Text] [Related]
6. Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors.
Pasternak GW; Childers SR; Snyder SH
Science; 1980 May; 208(4443):514-6. PubMed ID: 6245448
[TBL] [Abstract][Full Text] [Related]
7. Morphine catalepsy in the rat: involvement of mu 1 (high affinity) opioid binding sites.
Ling GS; Pasternak GW
Neurosci Lett; 1982 Oct; 32(2):193-6. PubMed ID: 6292799
[TBL] [Abstract][Full Text] [Related]
8. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.
Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
Neuroendocrinology; 1986; 42(1):75-81. PubMed ID: 3001565
[TBL] [Abstract][Full Text] [Related]
9. Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.
Holaday JW; Pasternak GW; Faden AI
Neurosci Lett; 1983 Jun; 37(2):199-204. PubMed ID: 6308526
[TBL] [Abstract][Full Text] [Related]
10. Identification of multiple opiate receptors through neuroendocrine responses. II. Antagonism of mu, kappa and sigma agonists by naloxone and WIN 44,441-3.
Pechnick R; George R; Poland RE
J Pharmacol Exp Ther; 1985 Jan; 232(1):170-7. PubMed ID: 2981314
[TBL] [Abstract][Full Text] [Related]
11. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model.
Ling GS; Paul D; Simantov R; Pasternak GW
Life Sci; 1989; 45(18):1627-36. PubMed ID: 2555641
[TBL] [Abstract][Full Text] [Related]
12. Opiates act centrally on GH and PRL release.
Panerai AE; Casanueva F; Martini A; Mantegazza P; Di Giulio AM
Endocrinology; 1981 Jun; 108(6):2400-2. PubMed ID: 7227313
[TBL] [Abstract][Full Text] [Related]
13. The effects of opiate agonists on growth hormone and prolactin release in rats.
Shaar CJ; Clemens JA
Fed Proc; 1980 Jun; 39(8):2539-43. PubMed ID: 6247214
[TBL] [Abstract][Full Text] [Related]
14. Naloxazone and pain-inhibitory systems: evidence for a collateral inhibition model.
Kirchgessner AL; Bodnar RJ; Pasternak GW
Pharmacol Biochem Behav; 1982 Dec; 17(6):1175-9. PubMed ID: 7163350
[TBL] [Abstract][Full Text] [Related]
15. Spinal and supraspinal opioid analgesia in the mouse: the role of subpopulations of opioid binding sites.
Ling GS; Pasternak GW
Brain Res; 1983 Jul; 271(1):152-6. PubMed ID: 6309332
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of morphine's analgesic and respiratory depressant actions.
Ling GS; Spiegel K; Nishimura SL; Pasternak GW
Eur J Pharmacol; 1983 Jan; 86(3-4):487-8. PubMed ID: 6299765
[No Abstract] [Full Text] [Related]
17. The effects of chronic naloxone on pituitary hormone secretion in female rats.
Gabriel SM; Simpkins JW; Millard WJ
Brain Res Bull; 1984 Apr; 12(4):359-62. PubMed ID: 6329481
[TBL] [Abstract][Full Text] [Related]
18. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment.
Yoburn BC; Goodman RR; Cohen AH; Pasternak GW; Inturrisi CE
Life Sci; 1985 Jun; 36(24):2325-32. PubMed ID: 2989632
[TBL] [Abstract][Full Text] [Related]
19. Naloxone does not reverse the inhibitory effect of morphine on luteinizing hormone secretion in prepubescent male rats.
Cicero TJ; Nock B; O'Connor L
J Pharmacol Exp Ther; 1993 Jan; 264(1):47-53. PubMed ID: 8380870
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine effects of dexmedetomidine: evidence of cross-tolerance between a mu-opioid agonist and an alpha 2-adrenoceptor agonist in growth hormone secretion of the male rat.
Idänpään-Heikkilä JJ; Rauhala P; Männistö PT
Pharmacol Toxicol; 1996 Mar; 78(3):136-42. PubMed ID: 8882345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
